메뉴 건너뛰기




Volumn 6, Issue 4, 2015, Pages 534-538

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics

Author keywords

Enzyme linked immunosorbent assay (ELISA); Immunotherapy; Lung cancer; PD L1

Indexed keywords


EID: 84934436823     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12247     Document Type: Article
Times cited : (116)

References (16)
  • 1
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 3
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer JR, Tykodi SS, Chow LQ etal. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
    • (2012) N Engl J Med , vol.366 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 4
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    • Herbst RS, Soria JC, Kowanetz M etal. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567.
    • (2014) Nature , vol.515 , pp. 563-567
    • Herbst, R.S.1    Soria, J.C.2    Kowanetz, M.3
  • 5
    • 80052476869 scopus 로고    scopus 로고
    • High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
    • Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28: 682-688.
    • (2011) Med Oncol , vol.28 , pp. 682-688
    • Mu, C.Y.1    Huang, J.A.2    Chen, Y.3    Chen, C.4    Zhang, X.G.5
  • 6
    • 84873666114 scopus 로고    scopus 로고
    • Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study
    • Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study. Tumori 2012; 98: 751-755.
    • (2012) Tumori , vol.98 , pp. 751-755
    • Chen, Y.B.1    Mu, C.Y.2    Huang, J.A.3
  • 7
    • 61549122071 scopus 로고    scopus 로고
    • Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma
    • Gao Q, Wang XY, Qiu SJ etal. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15: 971-979.
    • (2009) Clin Cancer Res , vol.15 , pp. 971-979
    • Gao, Q.1    Wang, X.Y.2    Qiu, S.J.3
  • 8
    • 84878962707 scopus 로고    scopus 로고
    • PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer
    • Song M, Chen D, Lu B etal. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS ONE 2013; 8 (6): e65821.
    • (2013) PLoS ONE , vol.8 , Issue.6 , pp. e65821
    • Song, M.1    Chen, D.2    Lu, B.3
  • 9
    • 84897404380 scopus 로고    scopus 로고
    • Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
    • Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014; 50: 1361-1369.
    • (2014) Eur J Cancer , vol.50 , pp. 1361-1369
    • Yang, C.Y.1    Lin, M.W.2    Chang, Y.L.3    Wu, C.T.4    Yang, P.C.5
  • 10
    • 84891534246 scopus 로고    scopus 로고
    • Programmed death ligand-1 expression in non-small cell lung cancer
    • Velcheti V, Schalper KA, Carvajal DE etal. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94: 107-116.
    • (2014) Lab Invest , vol.94 , pp. 107-116
    • Velcheti, V.1    Schalper, K.A.2    Carvajal, D.E.3
  • 11
    • 84874942318 scopus 로고    scopus 로고
    • Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
    • Kobayashi K, Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol 2013; 8: 27-33.
    • (2013) Target Oncol , vol.8 , pp. 27-33
    • Kobayashi, K.1    Hagiwara, K.2
  • 12
    • 32944472874 scopus 로고    scopus 로고
    • B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer
    • Simon I, Zhuo S, Corral L etal. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006; 66: 1570-1575.
    • (2006) Cancer Res , vol.66 , pp. 1570-1575
    • Simon, I.1    Zhuo, S.2    Corral, L.3
  • 13
    • 84901466325 scopus 로고    scopus 로고
    • Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications
    • Zheng ZX, Bu ZD, Liu XJ etal. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res 2014; 26: 104-111.
    • (2014) Chin J Cancer Res , vol.26 , pp. 104-111
    • Zheng, Z.X.1    Bu, Z.D.2    Liu, X.J.3
  • 14
    • 84920655625 scopus 로고    scopus 로고
    • PD-L1 and PD-1 expression in molecularly selected non-small cell lung cancer patients
    • D'Incecco A, Andreozzi M, Ludovini V etal. PD-L1 and PD-1 expression in molecularly selected non-small cell lung cancer patients. Br J Cancer 2015; 112: 95-102.
    • (2015) Br J Cancer , vol.112 , pp. 95-102
    • D'Incecco, A.1    Andreozzi, M.2    Ludovini, V.3
  • 15
    • 84923072443 scopus 로고    scopus 로고
    • Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
    • Azuma K, Ota K, Kawahara A etal. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014; 25: 1935-1940.
    • (2014) Ann Oncol , vol.25 , pp. 1935-1940
    • Azuma, K.1    Ota, K.2    Kawahara, A.3
  • 16
    • 84890020587 scopus 로고    scopus 로고
    • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
    • Akbay EA, Koyama S, Carretero J etal. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 12: 1355-1363.
    • (2013) Cancer Discov , vol.12 , pp. 1355-1363
    • Akbay, E.A.1    Koyama, S.2    Carretero, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.